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 
Abstract—Neuropeptide SF (NPSF) is a member of RFamide 
neuropeptides that play diverse roles in central nervous system. 
Little is know about the effects of NPSF on brain functions. 
Antidepressant-like effect of NPSF was studied in modified mice 
FST. NPSF showed the antidepressant-like effects by decreasing 
the immobility time and increasing the climbing and swimming 
time. Furthermore, the involvement of the adrenergic, 
serotonergic, cholinergic or dopaminergic receptors in the 
antidepressant-like effect of NPSF was studied in modified mice 
FST. Mice were pretreated with a non-selective α-adrenergic 
receptor antagonist phenoxybenzamine, a β-adrenergic 
receptor antagonist, propranolol, a 
non-selective 5-HT2 serotonergic receptor 
antagonist, cyproheptadine, nonselective muscarinic 
acetylcholine receptor antagonist, atropine, or D2, D3, D4 
dopamine receptor antagonist, haloperidol. The present results 
confirmed that the antidepressant-like effect of NPSF is 
mediated, at least in part, by an interaction of the α-adrenergic, 
5-HT2 serotonergic, muscarinic acetylcholine receptors and D2, 
D3, D4 dopamine receptor in a modified mouse FST. 
 
Index Terms — Neuropeptide SF (NPSF),FST, α-adrenergic, 
5-HT2 serotonergic, muscarinic acetylcholine receptors , D2, 
D3, D4 dopamine receptor . 
 
I. INTRODUCTION 
  Neuropeptide SF (NPSF) is an 11-membered aminoacid 
peptide classified in RFamide neuropeptide family that shares 
RFamide motifs in the C-terminal. Five groups of RFamide 
neuropeptides include gonadotropin-inhibitory hormone 
(GnIH), neuropeptide FF (NPFF), pyroglutamylated 
RFamide peptide (QRFP), prolactin-releasing peptide (PrRP) 
and Kisspeptin [1]. RFamide neuropeptides are involved in a 
wide variety of physiological, neurophysiological and 
behavioral functions such as feeding, pain control and so on 
[2].  
Antidepressant-like effects of neuropeptide AF (NPAF) and 
Kisspeptin were reported previously, but little is known about 
the functions of NPSF. NPSF was tested for 
antidepressant-like effects in modified forced swimming test 
(FST) in mice. Furthermore, the involvement of the 
adrenergic, serotonergic, cholinergic or dopaminergic 
receptors in the antidepressant-like effect of NPSF was 
studied in modified mice FST. Mice were pretreated with a 
non-selective α-adrenergic receptor antagonist 
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phenoxybenzamine, a β-adrenergic receptor 
antagonist, propranolol, a non-selective 5-HT2 serotonergic 
receptor antagonist, cyproheptadine, nonselective muscarinic 
acetylcholine receptor antagonist, atropine, or D2, D3,D4 
dopamine receptor antagonist, haloperidol. 
 
II. MATERIALS AND METHODS 
A. Animals 
CFLP male mice were kept and handled during the 
experiments in accordance with the instructions of the 
University of Szeged Ethical Committee for the Protection of 
Animals in Research. Each animal was used in the 
experiments only once. The animals were housed in cages in 
a room maintained at constant temperature (25 ± 1 °C) and on 
a 12-h dark–light cycle (lights on at 06:00–18:00 h) with free 
access to tap water and standard laboratory food. Seven days 
of recovery from surgery was allowed before the 
experiments. 
.  
B. Surgery 
The mice were implanted with a cannula introduced into 
the right lateral brain ventricle in order to allow 
intracerebroventricular (i.c.v.) administration. The 
polystyrene cannula was inserted stereotaxically into the 
ventricle at the coordinates 0.2 mm posterior, 0.2 mm lateral 
to the bregma, and 2.0 mm deep from the dural surface [3]. 
The cannula was secured with cyanoacrylate (Ferrobond) 
(Budapest, Hungary). The mice were allowed seven days to 
recover from surgery before any i.c.v. administration.  
C. Materials 
NPSF was purchased from Bachem (Bubendorf, 
Switzerland). Phenoxybenzamine hydrochloride was from 
Smith Kline & French (Herts, 
UK); propranolol hydrochloride was from ICI Ltd. 
(Macclesfield, UK); cyproheptadine hydrochloride was from 
Tocris (Bristol, UK); atropine was from EGYS (Budapest, 
Hungary); haloperidol was from G. Richter (Budapest, 
Hungary).  
NPSF was lyophilized in a quantity of 10 μg per ampoule 
and stored at −20 °C Immediately before the experiments. 
NPSF was dissolved in sterile pyrogen-free 0.9% saline and 
administered i.c.v. via the cannula in a volume of 2 μl. 
D. Forced swimming test 
The modified FST was conducted on the mice as reported 
previously [4]-[7]. The mice were forced to swim 
individually in a glass cylinder 12 cm in diameter and 30 cm 
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in height, filled with water to a height of 20 cm. The 
temperature of the water was adjusted to 25 ± 1 °C. The water 
was changed between the individual mice. A 15-min pretest 
session was followed 24 h later by a 3-min test 
session.  NPSF (0.25 μg/2 μl, 0.50 μg/2 μl 
and1.00 μg/2 μl i.c.v.) was administered 30 min before the 
test session. Physiological saline was used for the vehicle 
controls. A time-sampling technique was applied to score the 
durations of climbing, swimming and immobility. Climbing 
time was measured when the mouse was in an active vertical 
motion with its forelegs above the water level; swimming 
time was measured when the mouse was in horizontal motion 
on the surface of the water; and immobility time was 
measured when the mouse was in a upright position on the 
surface with its front paws together and making only those 
movements necessary to keep it afloat. 
 
E. Statistical analysis 
The two-way analysis of variance (ANOVA) test was 
followed by Tukey’s test for multiple comparisons with 
unequal cell size. Probability values (P) of less than 0.05 
versus the control and NPSF-administered group were 
considered significant 
III. RESULTS 
NPSF (0.25 μg/2 μl, i.c.v.) administered mice exhibited a 
significantly decreased immobility time [F (3, 49) = 17.31: P 
< 0.05], a significantly increased climbing time [F (3, 49) 
= 10.53: P < 0.05] and a significantly increased swimming 
time [F (3, 49) = 7.95: P < 0.05]. NPSF (0.50 μg/2 μl, i.c.v.) 
administered mice exhibited a significantly decreased 
immobility time [F (3, 49) = 17.31: P < 0.05], a significantly 
increased climbing time [F (3, 49) = 10.53: P < 0.05] and a 
significantly increased swimming time [F (3, 
49) = 7.95: P < 0.05]. NPSF (1.00 μg/2 μl, i.c.v.) 
administered mice exhibited a significantly decreased 
immobility time [F (3, 49) = 17.31: P < 0.05] and a 
significantly increased swimming time 
[[F (3) = 7.95: P < 0.05] (see Fig. I). 
 
Phenoxybenzamine per se (2 mg/kg, i.p.) did not affect the 
immobility time, climbing time and swimming time. 
Pretreatment with phenoxybenzamine did not affect the 
immobility time the swimming time, but decreased the 
climbing time of NPSF-treated mice [F (3.38) = 5.78: 
P < 0.05] (see Fig. II). 
Propranolol per se (5 mg/kg, i.p.) did not affect the 
immobility, climbing and swimming time and pretreatment 
with propranolol did not affect the immobility, climbing and 
swimming time of NPSF-treated mice time (data not shown).  
Cyproheptadine per se (3 mg/kg, i.p.) did not affect the 
immobility, climbing and swimming time and pretreatment 
with cyproheptadine did not affect the immobility time 
of NPSF-treated mice. Pretreatment 
with cyproheptadine decreased the climbing 
[F (3.40) = 8.12: P < 0.05] and swimming time of NPSF- 
treated mice [F (3.40) = 8.12: P < 0.05] (see Fig. III).  
Atropine per se (2 mg/kg, i.p.) did not affect the 
immobility, climbing and swimming time and pretreatment  
Fig. I The antidepressant-like effects of Neuropeptide SF 
(NPSF) in modified mouse forced swim test (FST). Control 
(N=18), NPSF 0.25 μg/2 μl, i.c.v. (N=11), NPSF 0.50 μg /2 
μl, i.c.v. (N=10), NPSF 1.00 μg /2 μl, i.c.v. (N=10). * : P < 
0.05 vs. control (N: the number of animals, P: probability) 
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Fig. II The effect of a nonselective α-adrenergic receptor 
antagonist, phenoxybenzamine (POB) in Neuropeptide 
SF (NPSF)-induced antidepressant-like action in 
modified mouse forced swim test (FST). Control (N=9), 
Neuropeptide SF 0.25 μg/2 μl, i.c.v. (N=9), 
Phenoxybenzamine (POB) 2.0 mg/kg, i.p. (N=10), 
Phenoxybenzamine (POB) 2.0 mg/kg, i.p. + Neuropeptide SF  
0.25 μg /2 μl, i.c.v. (N=10). *: P < 0.05 vs. control (N: the 
number of animals, P: probability). 
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with atropinedid not affect the immobility time 
of NPSF-treated mice time.  Pretreatment with atropine 
decreased the climbing [F (3.40) = 5.80: P < 0.05] and 
swimming time of NPSF-treated mice time [F (3.40) = 4.30: 
P < 0.05] (see Fig. IV). 
Haloperidol per se (10 μg/kg, i.p.) did not affect the 
immobility, swimming and  climbing time and pretreatment 
with haloperidol did not affect the climbing time 
of NPSF-treated mice time. Pretreatment with haloperidol 
increased the immobility time and decreased the swimming 
time of NPSF-treated mice time [F (3.55) = 6.83: P < 0.05] 
(Fig. 5). 
The results demonstrated that the antidepressant-like effect 
of NPSF is mediated, at least in part, by an interaction of the 
α-adrenergic, 5-HT2 serotonergic, muscarinic acetylcholine 
receptors and D2, D3, D4 dopamine receptor in a modified 
mouse FST. 
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Fig. III The effect of a nonselective 5-HT2 serotonergic 
receptor antagonist, cyproheptadine (CPH) in 
Neuropeptide SF (NPSF)-induced antidepressant-like 
action in modified mouse forced swim test (FST). Control 
(N=10), Neuropeptide SF 0.25 μg/2 μl, i.c.v. (N=10), 
Cyproheptadine (CPH) 3.0 mg/kg, i.p. (N=10), 
Cyproheptadine (CPH) 3.0 mg/kg, i.p. + Neuropetide SF 0.25 
μg /2 μl, i.c.v. (N=10). * : P < 0.05 vs. control (N: the number 
of animals, P: probability). 
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Fig. IV The effect of a nonselective muscarinic 
acetylcholine receptor antagonist, atropin (ATR) in 
Neuropeptide SF (NPSF)-induced antidepressant-like 
action in modified mouse forced swim test (FST). Control 
(N=10), Neuropeptide SF 0.25 μg/2 μl, i.c.v. (N=10), Atropin 
(ATR) 2.0 mg/kg, i.p. (N=10), Atropin (ATR) 2.0 mg/kg, i.p. 
+ Neuropetide SF 0.25 μg /2 μl, i.c.v. (N=10). * : P < 0.05 vs. 
control (N: the number of animals, P: probability). 
0
20
40
60
80
100
120
140
160
180
200
control Neuropeptide SF ATR ATR + NPSF
ti
m
e
 (
se
c
)
immobility
climbing
swimming
*
*
*
*
*
**
*
*
*
 
 
 
IV. DISCUSSION 
Since the first member of RFamide neuropeptides was 
discovered as cardioexcitatory peptide in invertebrates, many 
diverse group of N-terminal RFamide neuropeptides have 
been identified in the nervous system of higher animals [1]. 
Their roles in the central nervous system range from 
physiological processes to animal behaviors including 
feeding, pain control and so on [2]. 
Microinjection of RFRP-1 in the central nucleus of 
amygdala decreases food intake in the rat [8]. Central 
injection of neuropeptide AF reduces food intake in rats [9]. 
RFamides including prolactin-releasing peptide (PrRP) affect  
energy metabolism and neuroendocrine systems, playing a 
role in the control of energy metabolism and stress responses 
Fig. V The effect of a D2, D3,D4 dopamine receptor 
antagonist, Haloperidol (HPD) in Neuropeptide SF 
(NPSF)-induced antidepressant-like action in modified 
mouse forced swim test (FST). Control (N=13), 
Neuropeptide SF 0.25 μg/2 μl, i.c.v. (N=13), Haloperidol 
(HPD) 10 μg/kg, i.p. (N=14), Haloperidol (HPD) 10 μg/kg, 
i.p. + Neuropetide SF 0.25 μg /2 μl, i.c.v. (N=15). * : P < 0.05 
vs. control (N: the number of animals, P: probability). 
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[10]. Furthermore, administration of RFRPs induces 
anxiety-related behavior in rats in open-field test. NPSF 
augments paraventricular CRH release and increases ACTH 
and corticosterone levels in the plasma [11]. 
Intracerebral administration of Kisspeptin-13 stimulates 
HPA axis and causes anxiety in rats [12]. Intracerebral 
administration of neuropeptide AF induces anxiety-like and 
antidepressant-like behavior [13] 
The present study shows that NPSF has antidepressant-like 
effects in a modified FST of mice. Furthermore, the present 
results confirmed that the antidepressant-like effect of NPSF 
is mediated, at least in part, by an interaction of the 
α-adrenergic, 5-HT2 serotonergic, muscarinic acetylcholine 
receptors and D2, D3, D4 dopamine receptor in a modified 
mouse FST. 
 
ACKNOWLEDGMENT 
This work was supported by grants from TAMOP 
4.2.1/B-09 and the Hungarian Academy of Sciences. 
 
REFERENCES 
[1] G. K. Sandvik, K. Hodne, T. M. Haug, K. Okubo and F. A. Weltzien, 
“RFamide peptides in early vertebrate development,” Front 
Endocrinol. (Lausanne), vol. 5, 2014, p. 203. 
[2] D. A. Bechtold and S. M. Luckman, “The role of RFamide peptides in 
feeding,” J. Endocrinol., vol. 192, 2007, pp. 3-15. 
[3] A. S. Pellergrino and A. J. Cushman, Stereotaxic Atlas of the Rat Brain, 
New York, Plenum Press, 1979, pp. 8–57. 
[4] M. J. Detke, M. J. Rickels and I. Lucki, “Active behaviors in the rat 
forced swimming test differentially produced by serotonergic and 
noradrenergic antidepressants,” Psychopharmacology (Berl.), vol. 
121, 1995, pp. 66–72. 
[5] R. T. Khisti, C. T. Chopde and S. P. Jain, “Antidepressant-like effect of 
the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice 
forced swim test,” Pharmacol. Biochem. Behav., vol. 67, 2000, pp. 
137–143. 
[6] T. Hokfelt, T. Bartfai and F. Bloom, “Neuropeptides: opportunities for 
drug discovery,” Lancet Neuro., vol. 2, 2003, pp. 463–472. 
Antidepressant-like Effects of Neuropeptide SF (NPSF) 
 
                                                                                29                                                                 www.wjrr.org 
 
[7] R. D. Porsolt, M. Le Pichon and M. Jalfre, “Depression: a new animal 
model sensitive to antidepressant treatments,” Nature, vol. 266, 1977, 
pp. 730–732. 
[8] A. Kovács, K. László, R. Gálosi, K. Tóth, T. Ollmann, L. Péczely and 
L. Lénárd, “Microinjection of RFRP-1 in the central nucleus of 
amygdala decreases food intake in the rat,” Brain Res. Bull., vol. 88, 
2012, pp. 589-595. 
[9] B. A. Newmyer and M. A. Cline, “Neuropeptide AF is associated with 
short-term reduced food intake in rats,” Behav. Brain Res., vol. 219, 
2011, pp. 351-353. 
[10] Y. Takayanagi and T. Onaka, “Roles of prolactin-releasing peptide and 
RFamide related peptides in the control of stress and food intake,” J. 
Neuroendocrinol., vol. 23, 2011, pp. 20-27. 
[11] M. Kaewwongse, Y. Takayanagi and T. Onaka, “Effects of 
RFamide-related peptide (RFRP)-1 and RFRP-3 on oxytocin release 
and anxiety-related behaviour in rats,” Regul. Pept., vol. 188, 2014, pp. 
46-51. 
[12] M. Jászberényi, Z. Bagosi, K. Csabafi, M. Palotai and G. Telegdy, 
“The actions of neuropeptide SF on the hypothalamic-pituitary-adrenal 
axis and behavior in rats,” Regul. Pept., vol. 188, 2014, pp. 46-51. 
[13] M. Palotai, G. Telegdy, M. Tanaka, Z. Bagosi and M. Jászberényi, 
“Neuropeptide AF induces anxiety-like and antidepressant-like 
behavior in mice,” Behav. Brain Res., vol. 274, 2014, pp. 264-269. 
 
 
 
Masaru Tanaka, graduated from University of 
Szeged, Faculty of General Medicine, is currently 
working at Institute of Pathophysiology, 
Hungarian Academy of Science - University of 
Szeged (MTA-SZTE), Neuroscience Research 
Group, University of Szeged, Hungary.  Main 
area of research is antidepressant effects of 
neurohormonal peptides. He published several 
research papers in Behavioral Brain Research, 
Brain Research Bulltin, Neuropeptides, Regular 
peptides, etc.  
 
 
